| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | VAXX | Class A common stock | 226K | Jun 21, 2022 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VAXX | Stock option (right to buy) | Award | $0 | +129K | $0.00 | 129K | Jun 21, 2022 | Class A common stock | 129K | $2.09 | Direct | F1, F2, F3 | |
| holding | VAXX | Stock option (right to buy) | 94.2K | Jun 21, 2022 | Class A common stock | 94.2K | $4.30 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. |
| F2 | These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date. |
| F3 | These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. |
| F4 | These options are subject to a three-year time-vesting schedule, with 31,395 shares vesting on the first and second anniversaries of the grant date and the remainder vesting on the third anniversary of the grant date. |
| F5 | The expiration date was incorrectly reported as "03/31/2022" in the Form 4 filed on April 4, 2022. |